Neuronascent has published the Phase 1a clinical trial results for its lead investigational therapy NNI-362 in the journal Alzheimer’s Research and Therapy, according to the company. The study involved aged human subjects and reportedly found that NNI-362 was well tolerated and reduced plasma pTau181 levels—a pharmacodynamic marker—compared to pre-treatment values.
According to the company, the trial received support from the National Institute on Aging and, along with completed safety and manufacturing milestones, supports moving forward into Phase 2 trials in Alzheimer’s disease.
The company said that it has taken the first step toward testing NNI-362 in dogs with Canine Cognitive Disorder by securing a waiver of the Animal Drug User Fee Act sponsor fee from the FDA. This strategy aims to establish proof-of-concept in a natural model that mimics Alzheimer’s-like cognitive decline and may advance commercialization of the therapy.
Neuronascent claims that NNI-362 may benefit a range of age-related disorders characterized by neuron loss in cognitive and motor regions of the brain.
